Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for exclusive commercialization rights of Zeli Mei in China (excluding Hong Kong, Macau, and Taiwan), with a maximum upfront payment of 190 million yuan and milestone payments [1] - The collaboration is a significant milestone for Zedman in market expansion and resource complementarity, aiming to invigorate pediatric and dermatological drug offerings [1] - Zeli Mei is the first approved AhR modulator for treating eczema in children over 2 years old and adults, addressing clinical pain points of traditional treatments [2] Group 2 - Zedman Pharmaceutical's CEO emphasizes the importance of this collaboration for maximizing the innovative value of Zeli Mei and accelerating its internationalization [2] - Jichuan Pharmaceutical's General Manager highlights the strategic partnership as a key enhancement in pediatric and dermatological treatment product layout, filling a clinical gap for young eczema patients [3] - The partnership aims to leverage Jichuan's established sales network and academic promotion team to expedite the market introduction and clinical adoption of Zeli Mei [3]

Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for exclusive commercialization rights of Zeli Mei in China, excluding Hong Kong, Macau, and Taiwan [1] - Zedman will receive a maximum of 190 million yuan in upfront and milestone payments, including a maximum of 125 million yuan upfront and 65 million yuan for research milestones [1] - This collaboration marks a significant milestone in Zedman's market expansion and is a strategic move for resource complementarity and mutual benefits [1] Group 2 - Zeli Mei (Bimodamide Cream) is an innovative non-hormonal drug developed by Zedman, approved for treating eczema in children over 2 years old and adults, representing the first AhR modulator for this indication [2] - The drug works by suppressing inflammation, repairing skin barriers, regulating microbiota, and combating oxidative stress, addressing clinical pain points of traditional treatments [2] - Zedman’s CEO emphasized the importance of this partnership for maximizing the innovative value of Zeli Mei and accelerating its market promotion and clinical application in China [2] Group 3 - Jichuan Pharmaceutical's General Manager highlighted that this collaboration strengthens their product layout in pediatric and dermatological treatments, filling a clinical gap for young patients with eczema [2] - The partnership aims to leverage Jichuan's established sales network and specialized academic promotion team to expedite Zeli Mei's market entry and clinical adoption [2] - This initiative will enhance Jichuan's product matrix in pediatrics and dermatology, contributing to the development of skin health for children and adults in China [2]

Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Zedeman, allowing Jichuan to exclusively commercialize Zedeman's product, Zeli Me Benweimode Cream, in mainland China for a total payment of up to 190 million yuan (including tax) [1] Group 1 - Jichuan Pharmaceutical's subsidiary, Jichuan Pharmaceutical Group Co., Ltd., will be responsible for the commercialization of Zedeman's product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The total payment for the agreement, including upfront and milestone payments, will not exceed 190 million yuan [1] - This transaction is expected to enhance the product line of Jichuan Pharmaceutical, contributing to the sustainable development of the company's business and aligning with its strategic goals [1]

Core Insights - The "Digital Marketing Leadership Camp for Health Products" was launched in Beijing, focusing on the latest regulatory dynamics in pharmaceutical e-commerce, live marketing, and advertising compliance, featuring over ten senior operational experts from platforms like Douyin, Xiaohongshu, and JD.com [1][3] - The event emphasized three core areas: policy compliance, platform operation for growth, and cross-industry integration, providing a comprehensive knowledge system from policy understanding to practical execution for health enterprises [3][4] Policy Interpretation - The camp included expert interpretations of new policies, particularly focusing on the "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)," which aims to drive comprehensive upgrades in the pharmaceutical industry through digital and intelligent means [4] Platform Operations - The camp provided in-depth strategies for key platforms such as Douyin, Xiaohongshu, and JD.com, with frontline digital marketing operators sharing comprehensive methodologies from compliance basics to advanced operations, decoding mainstream channel rules and growth models [6] - Specific insights included Douyin's e-commerce platform rules and operational methods for brand growth, Xiaohongshu's content review requirements for health-related materials, and JD Health's complete empowerment system for pharmaceutical e-commerce [6] Cross-Industry Innovation - The camp explored cross-industry marketing, cutting-edge technology, and brand building, with discussions on how self-media can empower digital marketing for health products [7] - Emphasis was placed on the importance of building trust and value in the digital age, with insights from clinical professionals on the transformation of the physician's role and the need for compliance and effective value delivery in the new ecosystem [7][9] Training Outcomes - The three-day training program addressed the core demands of health enterprises for digital marketing, providing systematic solutions for growth and compliance, and received widespread acclaim from participants [9]

Core Insights - The "Digital Marketing Leadership Camp for Health Products" was launched in Beijing, focusing on compliance, platform operation, and cross-industry integration to enhance digital marketing effectiveness and innovation for enterprises [1][2]. Group 1: Event Overview - The event was organized by the China Pharmaceutical News Information Association and aimed to build a knowledge system from policy understanding to practical execution [1]. - It featured government regulatory leaders and experts who provided insights into new policies affecting the pharmaceutical industry, including the "Digital Transformation Implementation Plan for the Pharmaceutical Industry (2025-2030)" [1]. Group 2: Key Discussions - Experts analyzed the "Internet Advertising Management Measures" and the core content of the "Internet Advertising Identifiability Enforcement Guidelines" to clarify compliance requirements for digital marketing [1]. - The event included practical strategies for key platforms like Douyin, Xiaohongshu, and JD, with frontline operators sharing comprehensive methodologies for compliance and operational excellence in the health sector [2]. Group 3: Industry Perspectives - Medical professionals and executives from various companies discussed the transformation of doctors' roles and the importance of building trust in the digital age, emphasizing compliance and effective value delivery [2][3]. - The event facilitated discussions on innovative marketing strategies for prescription drugs, highlighting the importance of trust and commercial flow in driving e-commerce sales [2].

Core Insights - The trend of consumerization in pharmaceutical consumption is leading to increased patient involvement in treatment decisions, with safety and brand reputation becoming the primary considerations when purchasing medications [1] - The innovative non-hormonal drug, Zeli Mei Ben Wei Mo De Cream, is leading the market upgrade in the treatment of atopic dermatitis (eczema) [1] Industry Overview - Approximately 70 million eczema patients in China, with over 90% requiring topical treatments [2] - Traditional treatments have limitations such as limited efficacy, significant side effects, and a tendency for relapse after discontinuation [2] - Zeli Mei is the first globally approved aromatic hydrocarbon receptor modulator for eczema treatment in children over 2 years and adults, addressing the core issues of traditional therapies [2] Clinical Efficacy - Zeli Mei has shown a significant improvement in treatment outcomes, with nearly 60% of patients experiencing deep itch relief after 8 weeks, and over 80% efficacy in children [2] - In a Chinese Phase III clinical trial, 70% of patients remained relapse-free for 10 months after stopping treatment [2] - Clinical cases demonstrate rapid symptom relief, with 73% of pediatric patients showing significant improvement after treatment [3]

Core Insights - The collaboration between Zedman Pharmaceuticals and JD Health aims to provide affordable access to innovative treatments for patients with atopic dermatitis through a promotional campaign during JD's 11.11 shopping festival [1][2] - Zedman’s product, Zeli Mei cream, is the first aromatic receptor innovation drug approved for treating eczema in children over 2 years old and adults, demonstrating a high efficacy rate of 83.9% in clinical trials for children aged 7-11 [1] - The partnership emphasizes a comprehensive health management system that includes prevention, diagnosis, and treatment, enhancing JD Health's supply chain capabilities in dermatological products [1] Summary by Sections Collaboration Details - Zedman Pharmaceuticals and JD Health launched a "Caring for Patients" initiative, allowing patients to purchase Zeli Mei cream for only 10 yuan after receiving a 350 yuan coupon [1] - This initiative is part of a broader strategy to ensure patients have access to innovative treatment options through compliant drug supply channels [1] Product Information - Zeli Mei cream is a non-hormonal treatment for eczema, recognized for its safety and effectiveness, with mild to moderate adverse reactions reported [1] - The product has achieved a dual breakthrough in providing rapid itch relief and long-term skin repair [1] Previous Initiatives - In September, JD Health and Zedman initiated the "Health Escort, Safe Transition" campaign to support seasonal health issues, further expanding their collaboration in the dermatological sector [1] - The partnership leverages JD Health's full-chain capabilities in medical services, testing, diagnosis, and medication [1] Safety and Compliance - Zedman Pharmaceuticals values JD Health's strict identity verification, prescription review, and drug traceability systems, which ensure patient safety and respect for drug distribution regulations [2]

Core Viewpoint - The publication of the "Expert Consensus on the Treatment and Management of Atopic Dermatitis (2025 Edition)" provides standardized clinical application guidance for the innovative drug, Zhilimab Benmodem Cream, specifically for atopic dermatitis treatment in China [1] Group 1: Disease Prevalence and Treatment Options - The prevalence of atopic dermatitis among children in China is reported to be between 10% and 15% [1] - For mild to moderate cases, which account for two-thirds of patients, Zhilimab Benmodem Cream is recommended as an important treatment option based on research data from the Chinese population [1] Group 2: Mechanism and Approval - The aryl hydrocarbon receptor (AhR) is identified as a key mediator in the interaction between environmental factors and immune system components, playing a role in maintaining skin homeostasis and alleviating skin inflammation [1] - Zhilimab Benmodem Cream, developed by Shanghai Zedeman Pharmaceutical Technology Co., Ltd., is approved for the treatment of mild to moderate atopic dermatitis in children aged 2 years and older, with its market launch scheduled for November 2024 [1] Group 3: Consensus Development - The consensus was led by Professor Zhang Jianzhong from Peking University People's Hospital, involving 32 experts from dermatology, allergy, and pediatrics, and was established after four rounds of validation [1] - The consensus references 65 domestic and international research studies to create a standardized topical medication treatment system tailored to Chinese patients [1]

Core Insights - The "Expert Consensus on the Treatment and Management of Atopic Dermatitis (2025 Edition)" has been published, providing standardized clinical application guidance for the innovative drug, Zeli Mei Ben Wei Mo De Ointment [1][2] - Atopic dermatitis (AD) has a prevalence rate of 10%-15% among children in China, making it the leading non-fatal skin disease burden [1] - The consensus emphasizes the importance of Zeli Mei Ben Wei Mo De Ointment as a treatment option for the two-thirds of patients with mild to moderate AD, based on research data from the Chinese population [1][2] Treatment Mechanism - Zeli Mei Ben Wei Mo De Ointment works by inhibiting type 2 inflammatory cytokines and repairing the skin barrier, specifically targeting IL-4/IL-13 induced tight junction damage [2] - Clinical trials indicate that the ointment can reduce and eliminate skin lesions while alleviating itching, with most adverse reactions being mild to moderate [2] Treatment Guidelines - The consensus provides clear guidelines for treating special areas and populations, recommending the use of moderately potent topical medications in sensitive areas to avoid the risk of skin atrophy from long-term corticosteroid use [2] - The dual mechanism of Zeli Mei Ben Wei Mo De Ointment offers unique advantages in addressing the inflammatory responses and barrier defects commonly seen in AD patients in China, particularly for children and those contraindicated for steroids [2] - The publication of the consensus aims to guide medical institutions in standardizing the selection of topical medications for AD, promoting the standardization of AD diagnosis and treatment in China [2]

Core Insights - The 82nd American Academy of Dermatology Annual Meeting showcased significant clinical research data on the efficacy of Zeli Mei Ben Wei Mo De cream for treating atopic dermatitis (AD) in the Chinese population, highlighting its rapid itch relief, long-lasting efficacy, and safety profile [1][6]. Research Core Findings - Rapid Itch Relief: Zeli Mei cream demonstrated significant itch relief starting from day one of treatment, with a notable improvement on day two, showing a -5.2% change in average PP-NRS on day one and -8.0% on day two compared to the placebo group [2]. - Long-term Efficacy Maintenance: A one-year study indicated a high no-recurrence rate of 70% after discontinuation of the cream, showcasing its long-term disease control capabilities [2][4]. Research Details - Study Design: The multi-center, confirmatory clinical study involved 272 patients aged 2 years and older with moderate to severe AD across over 30 locations in China, using a randomized, double-blind, placebo-controlled method [3]. - Baseline Characteristics: The majority of the study population (52.2%) were children aged 2-17 years, with an average body surface area (BSA) of approximately 15%, indicating a wide coverage of age groups and disease severity [3]. - Efficacy Data Analysis: After 8 weeks of treatment, the Zeli Mei group achieved EASI75 and IGA response rates of 54.4% and 46.2%, respectively, significantly higher than the placebo group, demonstrating its effectiveness in improving skin lesions and overall disease control [3]. Safety Analysis - Adverse Reactions Overview: Among 193 patients treated with Zeli Mei cream, common adverse reactions included folliculitis (5.7%), pain (3.1%), and pruritus (3.1%), all classified as mild to moderate, with no severe adverse events reported [5]. - Safety Conclusion: The safety profile of Zeli Mei cream is favorable, indicating its suitability for long-term use [5]. Expert Opinions and Industry Significance - Experts highlighted the promising results of Zeli Mei cream in rapid itch relief and long-term disease alleviation, with a low recurrence rate of 70%, marking a new chapter in non-hormonal treatment for AD [6][7]. - The CEO of Zedman emphasized the global potential of Zeli Mei cream and the company's commitment to innovative drug development, enhancing China's international standing in the field of innovative drug research [7].